We are live on ! Find out more
CRMD icon

CorMedix

34 hedge funds and large institutions have $1.96M invested in CorMedix in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more capital invested

Capital invested by funds: $1.56M → $1.96M (+$396K)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.1% less ownership

Funds ownership: 2.12%2.02% (-0.1%)

3% less funds holding

Funds holding: 3534 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $19K

Holders
34
Holders Change
-1
Holders Change %
-2.86%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
5
Reduced
6
Closed
6
Calls
Puts
$19K
Net Calls
-$19K
Net Calls Change
+$21K

CRMD Hedge Fund Activity: Q2 2018 in Review

34 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q2 2018, worth a combined $1.96M — up 25% from $1.56M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CRMD and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $43.5K. The largest seller was Citadel Advisors, cutting an estimated $48.9K.

  • 34 institutional investors held CorMedix (CRMD) as of Q2 2018, down from 35 in Q1 2018.
  • Funds reported $1.96M of CorMedix stock for Q2 2018, up 25% quarter-over-quarter.
  • 5 funds opened new CorMedix positions in Q2 2018 and 6 closed out, a net change of -1 holder.
  • The largest CorMedix buyer in Q2 2018 was Virtu Financial, an estimated $43.5K added.
  • The largest CorMedix seller in Q2 2018 was Citadel Advisors, an estimated $48.9K sold.

Based on aggregated 13F filings for Q2 2018.